Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;99(10):950-960.
doi: 10.1097/PHM.0000000000001407.

Injectable Biologics: What Is the Evidence?

Eva Kubrova  1 , Ryan S D'Souza, Christine L Hunt, Qian Wang, Andre J van Wijnen, Wenchun Qu
Affiliations
Review

Injectable Biologics: What Is the Evidence?

Eva Kubrova et al. Am J Phys Med Rehabil. 2020 Oct.

Abstract

Injectable biologics have attracted considerable interest in the field of musculoskeletal medicine. Biologics encompass a broad and diverse group of human tissue-derived therapeutics. The most commonly reported biologics for use in musculoskeletal conditions include platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stem cells, microfragmented fat, stromal vascular fraction, amniotic membrane-based products, and autologous conditioned serum. The benefits of biologics in tissue healing and regeneration are thought to be derived from their trophic, paracrine, and immunomodulatory functions. The purpose of this review is to define commonly used injectable biologics and to appraise current evidence on its efficacy in the treatment of musculoskeletal disease.

PubMed Disclaimer

References

    1. Woolf AD, Pfleger B: Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646–56
    1. Revers L, Furczon E: An introduction to biologics and biosimilars. Part I: biologics: what are they and where do they come from?Can Pharm J 2010;143:134–9
    1. FDA: Framework for the Regulation of Regenerative Medicine Products. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ.... Published 2019. Accessed May 21, 2019
    1. FDA: Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Available at: https://www.fda.gov/media/109176/download. Published 2017. Accessed July 2019
    1. Marx RE: Platelet-rich plasma (PRP): what is PRP and what is not PRP?Implant Dent 2001;10:225–8

MeSH terms

Substances

LinkOut - more resources